Successful total hip arthroplasty in patients with anca-associated systemic vasculitis

The retrospective study enrolled 8 patients with ANCA-associated  systemic vasculitis (AASV) and hip joint (HJ) injury with indications for total hip arthroplasty (HA); a total of 11 HJs were operated on. The patients’ median age at the time of the first HA was 54 [31; 76] years. The median duration of follow-up after HA was 3 [0.5 to 12.5] years. Wegener’s granulomatosis was diagnosed in 5 patients; microscopic polyangiitis in 2 patients, and eosinophilic granulomatosis polyangiitis (or Churg-Strauss  syndrome) in one case. At the onset of AASV, the median Birmingham Vasculitis Activity Score (BVAS) was 12 [6; 26]; four patients had a 5-year mortality rate of 21% (Five-Factor Score (FFS)  = 1). AASV remission was induced by anti-B cell therapy with rituximab (RTM) in 6 patients. A total of 10 total HAs were performed for aseptic necrosis of the femoral head and another HA was carried out for a femoral neck fracture. At the time of HA, complete remission (BVAS = 0) was observed in 7 cases of AASV; incomplete remission (BVAS = 3) was seen in one patient. All endoprosthesis  components  were stable; there were no signs of osteolysis. In all cases, HA was successful in increasing HJ functional activity and in reducing pain (the Harris hip score averaged 54 before HA and 87 at 6 months after surgery). None of the patients had AASV recurrence  or developed postoperative complications  (except for the need for blood transfusion).

The authors’ own experience suggests that total HA is a potentially highly effective and relatively safe treatment in patients with AASV, including those with severe AASV and unfavorable prognostic factors. To reduce the risk of postoperative complications  (primarily thromboembolism, infections, and RTM-induced late-onset  neutropenia), total HA should be performed in the period of AASV remission under the control of comorbid conditions  and in the close cooperation  of rheumatologists  and orthopedic  surgeons. The following recommendations for the management of patients with rheumatic diseases should include patients with AASV for elective total HA.

1. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133

2. Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi: 10.1002/art.40149

3. Pavlov VP, Makarov SA, Khramov AE. Total hip replacement in patients with wide spectrum of rheumatic diseases. Meditsina (Kazakhstan). 2014;(10):36-40 (In Russ.).

4. Luqmani R, Bacon P, Moots R, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87(11):671-8.

5. Guillevin L, Pagnoux C, Seror R, et al; French Vasculitis Study Group (FVSG). The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011 Jan;90(1):19-27. doi: 10.1097/MD.0b013e318205a4c6

6. Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep. 2012 Dec;14(6):494-500. doi: 10.1007/s11926-012-0291-1

7. Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51:737-55. doi: 10.2106/00004623-196951040-00012

8. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi: 10.2174/1874312920131210005

9. Danoff JR, Moss C, Liabaud B, Geller JA. Total knee arthroplasty considerations in Rheumatoid Arthritis. Autoimmun Dis. 2013;2013:Article ID 185340, 6 p. doi: 10.1155/2013/185340 36

10. Khramov AE, Makarov MA, Byalik EI, et al. Periprosthetic joint infection in patients with rheumatic diseases: The problems of diagnosis, prevention, and treatment. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):558-63 (In Russ.). doi: 10.14412/1995-4484-2015-558-563

11. McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012;7(2):240-7. doi: 10.2215/CJN.05610611

12. Belov BS, Makarov SA, Byalik EI. Bacterial (septic) arthritis and prosthetic joint infection. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):192-200 (In Russ.). doi: 10.14412/1995-4484-2017-192-200

13. Lohmann C, Nuechtern J, Junk-Jantsch S, et al. Hypersensitivity reactions in total hip arthroplasty. Orthopedics. 2007;30. doi: 10.3928/01477447-20070901-12

14. Pavlov VP, Vardikova GN, Makarov SA, et al. Knee and hip joints endoprothesis in old and senile patients with rheumatic diseases. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(4):101-5 (In Russ.). doi: 10.14412/1995-4484-2003-1346

15. Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi: 10.1002/art.38231

16. Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi: 10.1136/annrheumdis-2012-202758

17. Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi: 10.1002/acr.22497

18. Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi: 10.3899/jrheum.151373

19. Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi: 10.1016/j.arth.2012.02.022

20. Beketova TV, Aleksandrova EN, Novoselova TM, et al. Russian experience with using monoclonal antibodies to Blymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the Russian Register NORMA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):147-58 (In Russ.). doi: 10.14412/1995-4484-2014-147-158

21. Rybnikov AV, Byalik EI, Reshetnyak TM, et al. The prevention of venous thromboembolism and the risk of postoperative complications in patients with rheumatoid arthritis and osteoarthritis after total hip arthroplasty. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):797-804 (In Russ.). doi: 10.14412/1995-4484-2018-797-804

22. Mochizuki T, Ikari K, Yano K, et al. Outcome of direct oral anticoagulant treatment for acute lower limb deep venous thrombosis after total knee arthroplasty or total hip arthroplasty. Mod Rheumatol. 2018;1:1-5. doi: 10.1080/14397595.2018.1504396

23. Januel JM, Romano PS, Couris CM, et al. Clinical and health system determinants of venous thromboembolism event rates after hip arthroplasty: An international comparison. International Methodology Consortium for Coded Health Information (IMECCHI). Med Care. 2018;56(10):862-9. doi: 10.1097/MLR.000000000000095

24. Johanson N, Lachiewicz PF, Licbcrman JR, et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroscopy. J Am Acad Orthop Surg. 2009;17(17):183-96. doi: 10.2106/JBJS.I.00511

25. D’Angelo A, Kluft C, Verheijen J, et al. Fibrinolytic shut down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor. Eur J Clin Invest. 1985;15:308-12 doi: 10.1111/j.1365-2362.1985.tb00277

26. Zoller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis. 2012;2(3):171-83.

27. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol. 2008 Dec;19(12):2421-9. doi: 10.1681/ASN.2008030270

28. Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost. 2019 Feb;45(1):86-93. doi:10.1055/s-0038-1677040

29. Maino A, Rossio R, Cugno M, et al. Hypereosinophilic syndrome, Churg-Strauss syndrome and parasitic diseases: possible links between eosinophilia and thrombosis. Curr Vasc Pharmacol. 2012 Sep;10(5):670-5. doi: 10.2174/157016112801784594

30. Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophilia and thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost. 2010 Dec;16(6):628-36. doi: 10.1177/1076029609348647

31. Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum. 2009 Nov;60(11):3493-500. doi: 10.1002/art.24957

32. Allenbach Y, Seror R, Pagnoux C, et al; French Vasculitis Study Group. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis. 2009 Apr;68(4):564-7. doi: 10.1136/ard.2008.099051

33. Hilhorst M, Winckers K, Wilde B, et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013 Dec;40(12):2042-6. doi: 10.3899/jrheum.130200

34. Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905